Direct Monitoring of Verapamil Level in Exhaled Breath Condensate Samples

Fariba Pourkarim1, Elaheh Rahimpour2, Maryam Khoubnasabjafari2, Vahid Jouyban-Gharamaleki4, Abolghasem Jouyban2,5,6

1Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
2Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
3Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
4Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
5Kimia Idea Pardaz Azarbayjan (KIPA) Science Based Company, Tabriz; University of Medical Sciences, Tabriz, Iran.

Article Info

Article History:
Received: 25 June 2018
Revised: 31 August 2018
Accepted: 2 September 2018
ePublished: 18 March 2019

Keywords:
-Verapamil
-Fluorescence enhancement
-SDS
-Biosensing

Abstract

Background: In this research, an enhanced fluorimetric assay was developed for the direct monitoring of verapamil in exhaled breath condensate (EBC). The method is based on a binding-induced rigidity inside the sodium dodecyl sulfate (SDS) micelle which eliminate collisional quenching and vibrational modes responsible for non-radiative decay. This process produces an enhancement in the emission intensity of verapamil.

Methods: Fluorescence intensity measurements were made at 15 °C on a FP-750 spectrophotometer with maximum excitation and emission wavelengths of 280 nm and 310 nm, respectively. The important parameters influencing the analytical signal in experimental steps were investigated and optimized. The method was validated with considering of the linearity, recovery and limit of detection.

Results: Under the optimized experimental conditions, the calibration graph was linear in the range of 0.02 − 12.0 µg·mL⁻¹ of verapamil with a detection limit of 0.008 µg·mL⁻¹.

Conclusion: The proposed method was found to be suitable and accurate for the determination of verapamil and the validated method was successfully used for analysis of verapamil in EBC of patients receiving verapamil with the satisfactory results.

Introduction

Verapamil, 5[(3,4-dimethoxyphenylethyl)methyl-amino]-2-(3,4-dimethoxyphenyl)-2-isopropyl-valeronitrile, as a L-type calcium channel blocker is widely used in the treatment of angina, arrhythmia, essential hypertension, certain cardiomyopathies, cluster headaches and modifying agent in tumors.1,2 Overdoses of this drug cause cardiac output decreasing, hypotension, and shock.3 It is mostly applied in two types of oral dosage of verapamil (40−180 mg and 120−140 mg in the case of commonly used tablets and slow releasing tablets, respectively).4 The therapeutic plasma concentration of verapamil has been reported in variable ranges from 20 to 500 ng·mL⁻¹ depending on drug form used.3 Optimal dosage of drugs is different for each person due to some parameters such as age, genetics, diet and medications taken concurrently. This shows that patients need frequent adjustments of individual dosage of drug due to individual variance in verapamil pharmacodynamics and/or individual variance in verapamil pharmacokinetics. Because of all these properties, determination of verapamil is one of considerable issues in analytical chemistry and clinical viewpoints.

Several analytical methods are reported in the literature for quantification of verapamil in plasma, urine, drugs and some other clinical samples. Some of these reports including fluorimetry,6 spectrophotometry,2,8 gas chromatography,6,11 ion-chromatography,13 HPLC,14−18 HPLC/MS−MS,9,19 LC−ESI−MS,21 SPME−LC−MS,22 MIP−LC−MS,23 and electrochemical methods.24 In spite of higher selectivity presented by above mentioned methods, most of them require sophisticated equipment and are costly, time consuming and also suffer from some disadvantages such as intricate and tedious operational procedure, and high material consumption which is quite inconvenient for for routine clinical applications. It is necessary for future individualized patient treatment to develop a simple, rapid and highly sensitive method for the monitoring of verapamil doses in the biological fluids. Knowing the drug concentration in body, make it possible for the physician to adjust the required drug dose before any unfortunate incident for the patient. Usually, plasma, serum or blood are used for the measuring drug concentrations. However, in compared with blood or other biological sample analysis, there are several advantages of exhaled breath condensate (EBC) tests.
EBC sampling, as a fairly accessible matrix, is easy to collect, repeatable, unassociated with side effects and any appreciable discomfort or risk to the subject.\textsuperscript{25} It also reduces the number of interfering compounds in compared with more intricate matrices such as blood, urine and other biological fluids. The studies show that many drugs or metabolites are exhaled and can potentially be applied as diagnostic biomarkers.\textsuperscript{26,27} So, EBC analysis may provide instantaneous information about a pharmacokinetics of drugs or subject’s health status.

To our knowledge, there are no reports of direct verapamil determination in the literature. To continue our earlier work on analysis of verapamil in EBC using a combination of dispersive liquid-liquid microextraction and spectrophotometric measurement of verapamil at 200 nm, in this study, we have attempted to enhance the inherent fluorescence of verapamil with rigidity-induced materials and to evaluate their performance for direct monitoring of verapamil in EBC samples. This method has outstanding advantages over existing methods with respect to sensitivity, determination range, facility, speed, and ease operation without any sample preparation methods such as extraction, separation and/or pre-concentration methods.

**Methods and Materials**

**Reagents and solutions**

All reagents were of analytical-reagent grade and ultrapure deionized water obtained from Shahid Ghazi Pharmaceutical Co. (Tabriz, Iran) was employed throughout the study. Sodium dodecyl sulfate (SDS, Carlo Erba, Milan, Italy), β-cyclodextrin (β-CD, Sigma, St Louis MO, USA), polyvinylpyrrolidone (PVP, Daana Pharmaceutical Company, Tabriz, Iran), cetyl trimethylammonium bromide (CTAB, Merck, Darmstadt, Germany) and verapamil hydrochloride (Sobhan Darou Pharmaceutical Company, Rasht, Iran) were used in this work. Standard stock (1000 µg·mL\(^{-1}\)) solution of verapamil was prepared by dissolving a proper amount of verapamil hydrochloride in methanol. Verapamil working solutions were prepared by dilution of the stock solution with ultrapure deionized water before each experiment.

**Apparatus and instruments**

Fluorescence intensity measurements were performed at 15 °C on a FP-750 spectrofluorometer (JASCO Corp., Japan) with 10 nm band-pass in both of the excitation and emission paths and the sensitivity of medium (except for verapamil concentration range of 0.5–12 µg·mL\(^{-1}\) which it was adjusted in low sensitivity). The instrument is equipped with a 150 W xenon lamp, 1.0 cm quartz cell, dual monochromators , Peltier thermostated single cell holder model ETC-272 (JASCO Corp., Japan), and supported with PC-based Windows® Spectra Manager TM software for JASCO Corporation. The UV–Vis absorption spectra were recorded on a double-beam UV–vis spectrophotometer model UV-1800 (Shimadzu, Japan) with 1.0 cm quartz cells. The pH adjustments of the used solutions were performed using a digital pH-meter model 744 (Metrohm Ltd., Switzerland) equipped with a glass-combined electrode. An electronic analytical balance model AB204-S (Mettler Toledo, Switzerland) was employed for weighing the materials.

**Exhaled breath condensate (EBC) collection**

EBC samples were collected by using a lab-made cooling trap system.\textsuperscript{28} EBC samples used for method validation were a pool of samples collecting from healthy subjects. Patient EBC samples were collected from three patients after oral administration of verapamil. Sample donors signed a written consent form approved by the Ethics Committee of Tabriz University of Medical Sciences.

**General procedure**

A proper aliquot of standard or sample solution containing verapamil in the range of 0.02–12 µg·mL\(^{-1}\) was placed into a 2 mL vial, then 80 µL of SDS solution (100 mmol·L\(^{-1}\)) was added. The solution was diluted with deionized water to 0.5 mL and mixed well. After 15 min the fluorescence intensity was recorded at 310 nm with excitation at 280 nm.

**Results and Discussion**

**Enhancement of fluorescence response**

The UV/Vis absorption spectra and fluorescence spectra of the verapamil (0.2 µg·mL\(^{-1}\)) in the absence and presence of SDS are shown in Figure 1. From the figures, it can be seen that verapamil in aqueous solution has a fluorescence with 280 nm excitation peak and about 310 nm emission peak. It is not observed any shift in the absorption peak of verapamil by adding SDS. However, it shows an increase in the absorbance intensity. The inherent fluorescence intensity of verapamil can be enhanced in the present of SDS as a rigidity-induced material due to micelle formation in the concentrations at above a critical micelle concentration (CMC) value (3.34 mmol·L\(^{-1}\)). It is well known that the non-radiative transition pathways always compete with the optical emission relaxation and cause usually dramatically decrease or, in some cases, e.g. low concentration of fluorophore, elimination of the emission. In the presence of such competition, the quantum yield of the fluorophore is reduced\textsuperscript{29,30} which can be considered an important issue especially in the low concentration of fluorophore and increase the detection limit.

In the other words, it may be said that the observed fluorescence enhancement of verapamil result from elimination of water molecules surrounding the verapamil and the decrease in their rotational freedom inside the SDS micelle which provide a protective environment for verapamil in excited state. This consequence with SDS and other rigidity-induced materials previously well assayed for fluorescent compound such as dapoxyl sodium sulphonate,\textsuperscript{31} graphitic carbon nitride quantum dots,\textsuperscript{32} 8-hydroxyquinoline,\textsuperscript{33} indole,\textsuperscript{34} benzene,\textsuperscript{35} and warfarin.\textsuperscript{36}
Signal intensity in analytical methods is frequently a challenge and hence the interest in techniques that produce amplified response signals has been intensely increased. We found that the fluorescence intensity of verapamil in the presence of SDS can be enhanced 1.7 orders which it provides an improvement in the detection limit of verapamil determination at least 5 orders of magnitude. Our previous study\(^3\) showed that the concentration range of verapamil in EBC of the patients receiving verapamil is about 0.07 to 0.1 µg.mL\(^{-1}\) which practically is not detectable without a preparation and/or pre-concentration method before the analysis. In that work, we used a dispersive liquid-liquid micro extraction technique coupled with HPLC-UV method for determination of verapamil in the patient’s EBC samples. Here, we used SDS for the enhancement of inherent fluorescence intensity of verapamil and without using any preparation and/or pre-concentration method before the analysis. In that work, we used a dispersive liquid-liquid micro extraction technique coupled with HPLC-UV method for determination of verapamil in the patient’s EBC samples. Here, we used SDS for the enhancement of inherent fluorescence intensity of verapamil and without using any preparation and/or pre-concentration method which reduced the limit of quantitation (LOQ) and limit of detection (LOD) values for direct determination of verapamil from 0.1 µg.mL\(^{-1}\) and 0.04 µg.mL\(^{-1}\) in the absence of SDS to 0.02 µg.mL\(^{-1}\) and 0.008 µg.mL\(^{-1}\) in the presence of SDS, respectively. Consequently, the concentration of verapamil could be monitored in the EBC of patient individuals by this developed method.

**Optimization of reaction condition**

In order to obtain the maximum fluorescence intensity, the effect of parameters which influence the analytical signal including type of rigidity induced material, pH, reagents concentration, temperature and incubation time were studied by one-at-a-time method. A 0.2 µg.mL\(^{-1}\) solution of verapamil was employed for all measurements and each experiment was repeated three times and mean values were reported.

**Type of rigidity–induced materials**

In this study various rigidity-induced materials including SDS, β-CD, CTAB, and PVP were examined as the protecting agents. As seen from Figure 2A, the sensitivity was much better in the presence of SDS than in its absence or in the presence of other protecting agents. It should be mentioned that, upon using the investigated agents, there is no changes observed in the position of the fluorescence maxima. All the used agents were studied in different concentrations including the concentrations of close and higher than the CMC for surfactants. Based on the obtained results, SDS with the concentration of 16 mmol.L\(^{-1}\) was selected as an appropriate rigidity-induced material for next experiments.

**Effect of pH**

The effect of pH was studied over a pH range of 5–12, using hydrochloric acid and sodium hydroxide solutions for pH adjustment. As shown in Figure 2B, a maximum fluorescence intensity for the analyte was obtained in the pH < 9. The \(pK_a\) of verapamil is 9.04,\(^3\) hence at pH < 9, verapamil is completely ionized and provides the positively charged nitrogen needed for strongly interaction with a negatively charged surfactants such as SDS. As the pH of EBC is within the range of 7–8, typical of that for human blood,\(^3\) the next experiments were performed without pH adjustment.

**Effect of temperature and incubation time**

The influence of determination temperature was also investigated at 15 to 35 °C. As CMC of surfactants can vary by changing the environmental conditions,\(^4\) the effect of temperature was studied in the concentration ranges of 4–32 mmol.L\(^{-1}\) for SDS. As can be seen from Figure 2C, decrease in temperature led to a considerable increase in the fluorescence intensity. However, in the case of temperature lower than 15 °C, it was observed a deformation in the spectra shape. So, 15 °C was recommended as an optimum temperature. Furthermore, the effect of the reaction time on the fluorescence response was investigated. As shown in Figure 2D, the fluorescence intensity increased and reached a constant value after 15 min.
Pourkarim F, et al.

Figure 2. Effect of (A) type of protecting agent and its concentration, (B) pH, (C) temperature and (D) time on the fluorescence intensity of verapamil. Concentration units: PVP: ×10⁻² w/v%, β-CD, SDS and CTAB: mmol·L⁻¹.

Figure 3. Effect of some co-administered drugs on the fluorescence intensity of verapamil. The concentrations of all drugs are 0.2 µg·mL⁻¹. (I) Verapamil, (II) verapamil + losartan, (III) verapamil + caffeine, (IV) verapamil + pantoprazole, and (V) verapamil + carvedilol.

Study of interferences
With the analytical procedure established at above optimized condition, the possible interference between verapamil and other co-administered drugs, several drugs (i.e. losartan, caffeine, pantoprazole, and carvedilol) were studied. For this purpose, 0.2 µg·mL⁻¹ of these species were added into the EBC sample spiked with standard solution of 0.2 µg·mL⁻¹ verapamil. The results are presented in Figure 3. As can be seen, all the drugs tested had no interference on the determination of verapamil (>10% is considered tolerated). These results showed that the method is selective for the analysis of verapamil in EBC samples.

Analytical figures of merit
The calibration graph in direct determination of verapamil in the absence of SDS was linear at 0.1 – 1 µg·mL⁻¹ with a detection limit of 0.04 µg·mL⁻¹. The equation for regression line was \( I_F = 558.28C + 129.93 \), where \( I_F \) is the fluorescence intensity in arbitrary unit, and \( C \) is the concentration of verapamil in µg·mL⁻¹. The calibration curve in the presence of SDS as a fluorescence enhancer was linear from 0.02 – 0.2 µg·mL⁻¹ verapamil with the equation \( I_F = 950.12C + 201.99 \) and from 0.5 – 12.0 µg·mL⁻¹ verapamil with the equation \( I_F = 59.267C + 24.905 \). Detection limits for each concentration range were 0.008 and 0.18 µg·mL⁻¹, respectively.
As can be seen, the dynamic linear range of verapamil concentration increase from 0.1 – 1 µg.mL⁻¹ in the absence of SDS to 0.02 – 12.0 µg.mL⁻¹ in the presence of SDS. It has also been observed in detection limit from 0.04 µg.mL⁻¹ to 0.008 µg.mL⁻¹. The precision of the method was investigated by repeated analysis of verapamil on the same day and on different days. The intra-day and inter-day relative standard deviations for four replicate determinations in two determined level were 0.72% and 1.6% for 0.2 µg.mL⁻¹ verapamil and 2.1% and 3.2% for 4 µg.mL⁻¹ verapamil, respectively.

**Real samples analysis**

The applicability of the validated method was tested by verapamil determination in three EBC samples taken from the patients receiving verapamil. The results are given in Table 1. As can be seen, the concentration of verapamil in sample number 1 is below the LOD value of validated method. In order to study the accuracy of the obtained results and providing an evidence for the interference of other co-administered drugs in determination of verapamil by this method, the sample number 1 was spiked with different levels of the known amount of verapamil and analyzed according to the general procedure. The obtained results are given in Table 2. The recoveries were 96% and 98% for two added amount of verapamil (i.e. 0.05 and 0.1 µg.mL⁻¹), indicating the good accuracy of the procedure and its independence from the matrix effects.

<table>
<thead>
<tr>
<th>No.</th>
<th>Gender</th>
<th>Age (year)</th>
<th>Daily dosage (mg)</th>
<th>Co-administered drugs</th>
<th>Concentration (µg.mL⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>72</td>
<td>40</td>
<td>Warfarin, Digoxin, Pirastam</td>
<td>&lt;LOD</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>44</td>
<td>40 BID⁺</td>
<td>–</td>
<td>0.067</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>68</td>
<td>40 BID⁺</td>
<td>Sodium valproate, Nitroglycerin, Ginkgo</td>
<td>0.059</td>
</tr>
</tbody>
</table>

*Two times a day

Table 1. Details of the real samples and found concentration of verapamil in patients' EBC samples

<table>
<thead>
<tr>
<th>Added amount (µg.mL⁻¹)</th>
<th>Found amount (µg.mL⁻¹)</th>
<th>Recovery (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05</td>
<td>0.048</td>
<td>96.0</td>
</tr>
<tr>
<td>0.1</td>
<td>0.098</td>
<td>98.0</td>
</tr>
</tbody>
</table>

*Details of sample donor of number 1 are given in Table 1.

**Conclusions**

In this work, a simple fluorescence based assay was validated for the direct determination of trace levels of verapamil in EBC of the patients receiving verapamil. Advantages of this method is utilizing a simple fluorimetry detection include the minimal time required to analyze samples without any sample preparation or pre-concentration steps which make it useful method for routine clinical applications. The method is based on an enhancement in the emission intensity of verapamil in the presence of SDS. We attribute the observed fluorescence enhancement of verapamil to the increased effective viscosity of the microenvironment inside the SDS micelle which constrains molecular motions of verapamil and causes a fluorescence enhancement. This method is simple, rapid, sensitive, reproducible and easy to use in routine applications.

**Acknowledgments**

We thank Sobhan Darou Pharmaceutical Company for gifting verapamil hydrochloride powder.

**Conflict of interests**

The authors declare that there is no conflict of interest.

**References**


Verapamil Level in Exhaled Breath Condensate


